Last update 30 May 2026

Anti-CD22 CAR T cell therapy(Bio-Raid)

Overview

Basic Info

Drug Type
CAR-T
Synonyms
anti-CD22 CAR-T therapy, Anti-CD22 chimeric antigen receptor T-cell therapies
Target
CD22
Action
modulators
Mechanism
CD22 modulators(CD22 modulators), Immunologic cytotoxicity, T lymphocyte replacements
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication-
Inactive Indication
CD22 Positive B-cell Acute Lymphoblastic LeukemiaDiffuse Large B-Cell LymphomaMarginal Zone B-Cell Lymphoma+ [1]
Originator Organization
Wuhan Bio-Raid Biotechnology Co., Ltd.Wuhan Bio-Raid Biotechnology Co., Ltd.
Active Organization-
Inactive Organization
Wuhan Bio-Raid Biotechnology Co., Ltd.Wuhan Bio-Raid Biotechnology Co., Ltd.
License Organization-
Drug Highest PhasePendingPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Anti-CD22 CAR T cell therapy(Bio-Raid)
NCT04007978
/ Unknown statusPhase 1IIT
Efficacy and Safety of Anti-CD22 CAR-T Therapy in Patients With Relapsed/Refractory B-cell Malignancies: a Single-center, Open-label, Single-arm Clinical Study
100 Clinical Results associated with Anti-CD22 CAR T cell therapy(Bio-Raid)
Login to view more data
100 Translational Medicine associated with Anti-CD22 CAR T cell therapy(Bio-Raid)
Login to view more data
100 Patents (Medical) associated with Anti-CD22 CAR T cell therapy(Bio-Raid)
Login to view more data
100 Deals associated with Anti-CD22 CAR T cell therapy(Bio-Raid)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CD22 Positive B-cell Acute Lymphoblastic LeukemiaPhase 1
China
Wuhan Bio-Raid Biotechnology Co., Ltd.Wuhan Bio-Raid Biotechnology Co., Ltd.
05 Aug 2019
Diffuse Large B-Cell LymphomaPhase 1
China
Wuhan Bio-Raid Biotechnology Co., Ltd.Wuhan Bio-Raid Biotechnology Co., Ltd.
05 Aug 2019
Marginal Zone B-Cell LymphomaPhase 1
China
Wuhan Bio-Raid Biotechnology Co., Ltd.Wuhan Bio-Raid Biotechnology Co., Ltd.
05 Aug 2019
Precursor B-Cell Lymphoblastic Leukemia-LymphomaPhase 1
China
Wuhan Bio-Raid Biotechnology Co., Ltd.Wuhan Bio-Raid Biotechnology Co., Ltd.
05 Aug 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free